Treatment
How Significant is a JAK2 Inhibitor as a Treatment for Myelofibrosis?
There’s one approved JAK2 inhibitor medicine and more coming. While they are not a cure for myelofibrosis, in the opinion of a leading researcher, Dr. Srdan Verstovsek from MD Anderson Cancer,…
A quote for you...
Powered By Optimism Quotes
Myelofibrosis: Now and What’s Coming for Treatment
Dr. Moshe Talpaz, world renowned myeloid disease specialist from the University of Michigan, explains the continuing progress in the treatment of myelofibrosis and the promise of better treatments to come. Dr. Talpaz expresses his excitement for the ongoing research in this challenging and at times frustrating condition. With the discovery… Continue reading
Cell Therapeutics Phase 3 PERSIST-1 Trial of Pacritinib for the Treatment of Myelofibrosis Begins
Press Release
SEATTLE, Jan. 9, 2013 /PRNewswire/ — Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today announced that the Company has initiated clinical trial sites and began enrolling patients in a Phase 3 clinical trial, known as PERSIST-1 or PAC325, for pacritinib, CTI’s investigational JAK2 inhibitor, which is being… Continue reading
Survivor Interview Karen T.
Karen is a myelofibrosis survivor. She talks about managing graft versus host disease after receiving a bone marrow transplant, dealing with diabetes, and planning for her financial future.
A quote for you...
Powered By Optimism Quotes
MYELOFIBROSIS_1.swf
A personal patient documentary on his treatment for myelofibrosis
A quote for you...
Powered By Optimism Quotes
Survivor Interview Karen T.
Karen is a myelofibrosis survivor. She talks about managing graft versus host disease after receiving a bone marrow transplant, dealing with diabetes, and planning for her financial future.
A quote for you...
Powered By Optimism Quotes